News

Company expands pipeline into car‑t and genetic medicine

Early findings support phase 2 plans for 2027

Call aims to support research preventing deadly newborn infections

Guidance supports use when standard therapies fail

Boehringer reports cardiometabolic improvements in people with t2d

Collaboration aims to accelerate atrial fibrillation pipeline

Early‑stage study to assess safety and efficacy signals

Biosimilar launch strengthens Teva’s oncology portfolio

Deal adds bioanalytical expertise in Australia

First pharmacological option for early intervention

Approval gives patients access to new targeted option

New indication adds oral option for young patients

Acquisition adds new frataxin‑targeted modalities

Phase 2 data show strong safety and immunogenicity

Half of patients remained progression-free without maintenance